Wave Life Sciences Ltd.
Description
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
About
CEO
Dr. Paul B. Bolno M.B.A., M.D.
Employees
266
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
Marina One East Tower, Singapore, 018936, Singapore
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 10, 2025 | — | — | — | — |
| Aug 6, 2025 | — | — | — | — |
| May 7, 2025 | — | — | — | — |
| Mar 4, 2025 | — | — | — | — |
| Nov 12, 2024 | -0.28 | -0.47 | -0.19 | 67.86% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 8 |
| Average estimate | — | -0.27 | — | -0.97 |
| Low estimate | — | -0.32 | — | -1.15 |
| High estimate | — | -0.24 | — | -0.67 |
| Last year EPS | — | -0.24 | — | -1.19 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-61.910%
Next qtr. (Mar 2025)
-12.500%
Current year
-120.110%
Next year (Dec 2025)
18.280%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 113.31M | 3.65M | 40.96M | 20.08M | 15.98M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 130.01M | 115.86M | 121.88M | 130.94M | 175.43M |
| Selling general and admin | 51.29M | 50.51M | 46.11M | 42.51M | 48.87M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -68.00M | -162.72M | -127.02M | -153.38M | -208.32M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | — | — | — | — | — |
| Other income expense | 9.81M | 1.58M | 4.57M | 2.63M | 14.65M |
| Pretax income | -58.19M | -161.14M | -122.45M | -150.75M | -193.64M |
| Tax provision | -677,000 | 681,000 | -204,000 | -841,000 | — |
| Net income | -57.51M | -161.82M | -122.25M | -149.91M | -193.64M |
| Basic EPS | -0.54 | -2.05 | -2.36 | -3.82 | -5.72 |
| Diluted EPS | -0.54 | -2.05 | -2.36 | -3.82 | -5.72 |
| Basic average shares | 106.10M | 78.86M | 51.83M | 39.23M | 33.87M |
| Diluted average shares | 106.10M | 78.86M | 51.83M | 39.23M | 33.87M |
| EBITDA | -66.72M | -154.18M | -117.21M | -143.96M | -204.03M |
| Net income from continuing op. | -57.51M | -161.82M | -122.25M | -149.91M | -193.64M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 274.95M | 146.39M | 207.01M | 279.24M | 284.25M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 200.35M | 88.50M | 150.56M | 184.50M | 147.16M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 21.09M | — | — | 30.00M | 20.00M |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 9.91M | 7.93M | 6.58M | 10.43M | 9.63M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 4.02M | 2.11M | 5.42M | 5.11M | 8.69M |
| Non current assets | |||||
| Properties | 22.64M | 26.84M | 18.38M | 16.23M | 18.10M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 26.97M | 26.40M | 26.47M | 26.10M | 25.06M |
| Construction in progress | 294,000 | 318,000 | 28,000 | 78,000 | 486,000 |
| Leases | 28.53M | 28.41M | 27.99M | 27.91M | 27.83M |
| Accumulated depreciation | -42.71M | -37.85M | -32.23M | -24.89M | -17.00M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 3.86M | 3.72M | 3.80M | 3.77M | 44.31M |
| Total liabilities | 235.32M | 191.48M | 174.51M | 196.46M | 220.52M |
| Current liabilities | |||||
| Accounts payable | 12.84M | 16.92M | 7.28M | 13.80M | 9.07M |
| Accrued expenses | 2.76M | 5.27M | 4.68M | 2.97M | 7.52M |
| Short term debt | 6.71M | 5.50M | 4.96M | 3.71M | 3.24M |
| Deferred revenue | 150.06M | 31.56M | 37.10M | 91.56M | 89.65M |
| Tax payable | — | — | — | — | — |
| Pensions | 14.07M | 12.29M | 10.18M | 9.00M | 8.66M |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 25.40M | 32.12M | 24.96M | 25.59M | 29.30M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | 190,000 | — | 474,000 | 1.72M |
| Shareholders equity | |||||
| Common stock | 935.37M | 802.83M | 749.85M | 694.09M | 539.55M |
| Retained earnings | -1.02B | -967.34M | -805.51M | -683.27M | -533.36M |
| Other shareholders equity | -124,000 | -29,000 | 181,000 | 389,000 | 267,000 |
| Total shareholders equity | 39.63M | -45.09M | 32.50M | 82.78M | 63.73M |
| Additional paid in capital | 129.24M | 119.44M | 87.98M | 71.57M | 57.28M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -57.51M | -161.82M | -122.25M | -149.91M | -193.64M | -146.65M | -101.98M | -55.66M | -19.20M | -5.23M | -3.32M |
| Depreciation | 9.21M | 10.11M | 9.84M | 9.98M | 9.20M | 5.58M | 2.16M | 784,000 | 594,000 | 281,000 | 276,000 |
| Deferred Taxes | — | — | — | — | — | — | 908,000 | -1.01M | 36,000 | 84,000 | -330,000 |
| Stock-Based Compensation | 9.80M | 17.19M | 16.41M | 14.30M | 19.51M | 15.60M | 12.14M | 6.85M | 4.02M | — | — |
| Other Non-Cash Items | — | — | — | — | — | 183,000 | 3.39M | 565,000 | 88,000 | -6,000 | -6,000 |
| Accounts Receivable | -21.09M | — | 30.00M | 20.00M | 10.00M | -59.00M | -1.00M | — | 193,000 | -129,000 | -102,000 |
| Accounts Payable | -3.76M | 9.35M | -6.57M | 5.12M | -3.50M | 4.94M | 3.89M | 3.37M | 1.65M | 9,000 | -152,000 |
| Other Assets & Liabilities | 46.63M | -3.97M | -23.16M | -10.45M | -27.59M | 152.42M | -4.50M | 12.22M | -114,000 | 152,000 | — |
| Operating Cash Flow | -16.73M | -129.14M | -95.73M | -110.96M | -186.01M | -26.94M | -85.00M | -32.88M | -12.73M | -4.84M | -3.63M |
| Investing Activities | |||||||||||
| Capital Expenditures | -1.12M | -1.26M | -560,000 | -1.34M | -3.92M | -9.94M | -18.89M | -5.56M | -1.85M | -257,000 | -47,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | -75.04M | — | — | — | — | — | — | — | — | — |
| Sale of Investments | — | 75.04M | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | -1.12M | -1.26M | -560,000 | -1.34M | -3.92M | -9.94M | -18.90M | -8.16M | -2.91M | 62,000 | -47,000 |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | -16,000 | -62,000 | -62,000 | -126,000 | — | -2.50M |
| Other Financing Charges | — | — | — | — | — | — | — | -1.08M | 112,000 | 34,000 | — |
| Financing Cash Flow | 131.28M | 52.33M | 54.97M | 153.63M | 161.79M | 59.98M | 93.45M | 28.86M | 175.59M | 5.62M | 1.17M |
| Other Cash Details | |||||||||||
| End Cash Position | 204.05M | 92.16M | 154.22M | 188.15M | 150.81M | 178.44M | 146.11M | 153.89M | 161.22M | 1.05M | 439,000 |
| Income Tax Paid | — | — | — | — | — | — | 11,000 | 554,000 | — | — | — |
| Interest Paid | — | — | — | — | — | — | 37,000 | 29,000 | — | 86,000 | 90,000 |
| Free Cash Flow | -20.55M | -129.14M | -89.55M | -117.32M | -192.15M | -32.80M | -102.56M | -37.49M | -14.38M | -5.02M | -3.60M |
Error: Invalid format in Holders JSON file.
Article
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation)
Feb 6, 2025
Article
Wave Life Sciences Is A Buy On Pipeline Prospects
Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and positive trial results have significantly boosted WVE's stock, despite previous flat performance and management missteps. Financially strong with $525M in cash, the Company has a solid runway for 8–10 quarters, though approval for its programs is still years away.
Jan 8, 2025
Article
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration
Dec 23, 2024
